• Oxeia Initiates Trial for OXE103 for Concussions americanpharmaceuticalreview
    October 28, 2020
    Oxeia Biopharmaceuticals announced the initiation of a Phase 2 clinical trial of OXE103 for treating concussion. The Phase 2 clinical study is being conducted by Dr. Michael Rippee, an assistant professor of neurology at the ...
PharmaSources Customer Service